Bystolic (nebivolol) / Menarini, AbbVie - LARVOL DELTA

Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT) (clinicaltrials.gov) - P=N/A | N=4537 | Recruiting | Sponsor: A.Menarini Asia-Pacific Holdings Pte Ltd

New trial • Cardiovascular • Hypertension

In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach. (PubMed, Drug Metab Dispos) - "We selected multiple probe substrates for CYP1A2 (caffeine, tizanidine, phenacetin), CYP2C9 ((S)-acenocoumarol, glimepiride, lornoxicam, tolbutamide, (S)-warfarin), CYP2C19 ((S)-lansoprazole, omeprazole, pantoprazole), CYP2D6 (desipramine, metoprolol, nebivolol, tolterodine), and CYP3A4 (alprazolam, felodipine, midazolam, nisoldipine, sildenafil, triazolam) to calculate the representative RAF value for each P450 isoform based on the in vivo-to-in vitro clearance ratio of the multiple probe substrates...The fm values of the responsible P450 isoform(s) could be well predicted for mexiletine, tamsulosin, risperidone, celecoxib, and glibenclamide...By applying relative activity factor values obtained from multiple probe substrates, this study was able to quantitatively predict the in vivo clearances mediated by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This simple, practical method will help optimize metabolic clearances via the major cytochrome P450..."

Journal • Preclinical • CYP1A2 • CYP2C19 • CYP2C9 • CYP3A4

DANBLOCK: Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (clinicaltrials.gov) - P4 | N=2760 | Active, not recruiting | Sponsor: Bispebjerg Hospital | Trial completion date: Apr 2025 ➔ Dec 2035

Trial completion date • Cardiovascular • Congestive Heart Failure • Myocardial Infarction

A CASE REPORT OF SWALLOWING INDUCED ATRIAL TACHYCARDIA - Travis Hanson (ACC 2025) - "This 46-year-old male with palpitations, intermittent chest pain, and lightheadedness while swallowing was diagnosed with SIAT. The patient's symptoms have been well managed with metoprolol and diltiazem."

Case report • Clinical • Cardiovascular • Pain

EFFICACY OF NEBIVOLOL/VALSARTAN COMBINED PILL FOR ANTI-HYPERTENSIVE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS - Talal Warsi (ACC 2025) - "The N/V combination pill significantly reduces systolic blood pressure SBP in comparison to valsartan, valsartan/amlodipine, or nebivolol, and DBP relative to nebivolol. However, it is important to consider limitations such as small sample size, lack of gender-specific data, and unreported adverse effects. Further comprehensive studies are needed to support the safety and effectiveness of N/V combination pills in different demographic subgroups."

Retrospective data • Review • Cardiovascular • Hypertension

Nebivolol rescued the liver and kidney from the coadministration of rivaroxaban and cisplatin by targeting inflammation, oxidative stress, and apoptosis in rats. (PubMed, Int Immunopharmacol) - "Moreover, nebivolol lowered the levels of caspase-3 in the liver and NF-κB in the kidneys. In conclusion, our study indicates that nebivolol protects the liver and kidneys from the detrimental effects of cisplatin and rivaroxaban."

Journal • Preclinical • Hepatology • Inflammation • Liver Failure • Oncology • Solid Tumor • CASP3 • IL6 • NFKB1 • TNFA

Mechanisms of nebivolol-mediated effects on bFGF-induced vascular smooth muscle cell proliferation and migration. (PubMed, Curr Res Pharmacol Drug Discov) - "The enhancement on bFGF-induced cell proliferation at lower concentrations appears to be mainly mediated by activation of β3-ARs but the inhibitory effects on bFGF-mediated cell proliferation as well as migration may occur through different mechanisms. AKT signaling is only involved in high concentrations of nebivolol-mediated effects."

Journal

An Energy Metabolism Nanoblocker for Cutting Tumor Cell Respiration and Inhibiting Mitochondrial Hijacking from Cytotoxic T Lymphocyte. (PubMed, Adv Healthc Mater) - "In this study, a CD44 receptor-targeted hyaluronic acid energy metabolism nanoblocker is developed to achieve bidirectional blockade of basal respiration in tumor cells with the loaded mitochondrial oxidative phosphorylation (OXPHOS) inhibitor nebivolol hydrochloride, and the glycolysis inhibitor 3-bromopyruvate...This emerging strategy, which involves depleting tumor cell energy through inhibition of basal respiration (OXPHOS/glycolysis) and extra respiration, while synergistically enhancing effector immune cells to maintain systemic anti-tumor immune effects, demonstrates high efficacy and safety in both in vitro and in vivo experiments. It provides a conceptual paradigm shift in nanomedicine-mediated energy metabolism-based tumor therapy."

Journal • Oncology

Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study. (PubMed, Clin Hypertens) - P=N/A | "These findings suggest the presence of other mechanisms in addition to sympathetic inhibition which potentially weaken the relationship between baseline PR and BP reduction. ClinicalTrials.gov Identifier: NCT03847350."

Journal • Real-world evidence • Cardiovascular • Hypertension

Membranous Nephropathy after mRNA 1273 (NKF-SCM 2025) - "mRNA 1273.214 was given one month prior.Results Creatinine is 1.01 to 1.40 mg/dl...Light microscopic, immunofluorescence staining for IgG, and electron microscopy specimens are shown below:Conclusion The patient was maintained on telmisartan, nebivolol, dapagliflozin, metformin, glipizide, evolocumab, and atorvastatin...Boosting with five doses of the vaccine and exposure to the Covid-19 virus may all have exacerbated this autoimmune response. The diminution of proteinuria from 2888 milligrams to 2112 milligrams 21 days later to 203 mg nineteen months after the final vaccine administration suggest that the antigen antibody complexes deposited in the glomerular basement membrane cleared and that the biopsy documented membranous nephropathy at the time of the acute proteinuria has resolved."

Glomerulonephritis • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Oncology • Renal Disease • C1QB • NELL1

Nebivolol attenuates acute systemic inflammation induced testicular dysfunction by decreasing transendothelial migration via VCAM-1/MMP-9 signaling. (PubMed, J Mol Histol) - "NB administration successfully restored all these changes significantly. Thus, NB can be a protective drug candidate for testicular dysfunction secondary to systemic inflammation with its potent antioxidant and anti-inflammatory mechanisms."

Journal • Inflammation • Oncology • CASP3 • MMP9 • TNFA • VCAM1

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging (clinicaltrials.gov) - P2 | N=5 | Terminated | Sponsor: Stanford University | N=360 ➔ 5 | Trial completion date: Jun 2025 ➔ Oct 2024 | Suspended ➔ Terminated; Low recruitment, insufficient funding

Enrollment change • Trial completion date • Trial termination • Cardiovascular

Target the Heart: a new axis of Alzheimer's disease prevention. (PubMed, bioRxiv) - "This indicates that co-administering a low dose of cyclosporine A with select cardiac drugs could be a potentially effective treatment strategy for Alzheimer's disease and cardiovascular dysfunction, while mitigating side effects associated with higher doses of cyclosporine A. Given that heart disease precedes Alzheimer's disease in many patients, physicians may be able to create a treatment regimen that simultaneously addresses both conditions. Our results suggest that cyclosporine A combined with simvastatin, irbesartan, cilostazol, doxazosin, or nebivolol are the most promising candidates for future exploration."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Heart Failure

Comparison of nebivolol, carvedilol, and bisoprolol for adverse clinical outcomes among patients with heart failure-a real-world nationwide investigation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Nebivolol cohorts had a lower risk of CV deaths and all-cause deaths than the non-BB cohort (adjusted HR = 0.77, 95% CI = 0.69-0.85; adjusted HR = 0.78, 95% CI = 0.73-0.83). The authors concluded that the use of nebivolol was associated with better outcomes in patients with HF."

Adverse events • Clinical data • Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Role of β-Adrenergic Receptors in Stress-Induced Cardiac Injury. (PubMed, Bull Exp Biol Med) - "β1-AR antagonists nebivolol and atenolol almost completely prevented SICI. Stimulation of β2-AR enhances cardiac tolerance to stress. β3-AR are not involved in the pathogenesis of SICI."

Journal

EVANESCENT-DPN: Evaluating a Nitric Oxide Generator, Nebivolol As a Disease Modifier in Patients with Diabetic Neuropathy. (clinicaltrials.gov) - P2/3 | N=120 | Recruiting | Sponsor: St. John's Research Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Neuropathy • Pain

Microvascular dysfunction causing myocardial ischemia in obstructive hypertrophic cardiomyopathy. (PubMed, Radiol Case Rep) - "The patient was treated with nebivolol and verapamil, leading to symptom relief and a reduction in the pressure gradient of LVOTO at follow-up. Effective management of HCM with MVD includes pharmacological therapy to alleviate outflow obstruction and improve myocardial perfusion. Comprehensive diagnostic and treatment approaches are essential for optimizing outcomes in patients with this complex condition."

Journal • Cardiomyopathy • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Hypertrophic Cardiomyopathy • Myocardial Ischemia • Psychiatry

An mTOR inhibitor discovery system using drug-sensitized yeast. (PubMed, Geroscience) - "Inhibition of the target of rapamycin (TOR/mTOR) protein kinase by the drug rapamycin extends lifespan and health span across diverse species...In contrast, 100 nM Torin1 and 500 nM GSK2126458 (omipalisib) are sufficient to identify TOR1-dependent growth inhibition in the drug-sensitized background...Additionally, for the TOR inhibitor AZD8055, the drug-sensitive system resolves that the compound results in TOR1-dependent growth sensitivity at 100 µM, whereas no growth inhibition is observed in a wild-type yeast strain background. Our platform also identifies the caffeine analog aminophylline as a TOR1-dependent growth inhibitor via selective tor1 growth sensitivity. We also tested nebivolol, isoliquiritigenin, canagliflozin, withaferin A, ganoderic acid A, and taurine and found no evidence for TOR inhibition using our yeast growth-based model. Our results demonstrate that this system is highly effective at identifying compounds that inhibit the TOR..."

Journal • Oncology

Is there a role for substituting non-vasodilatory beta-blockers in managing hypertension in CKD ? (ISN-WCN 2025) - "Methods 100 consecutive CKD pts (stage 1-5 ND) on a non-vasodilatory betablocker( Metoprolol(M) / Atenolol (A)/Carvedilol (C) ) amongst other antihypertensives, underwent BBP and CBP measurement with PulseCor device (suprasystolic oscillometry). Conclusions Nebivolol is more effective than non-vasodilatory beta-blockers, especially in controlling central blood pressure in CKD patients. Combining Nebivolol with Calcium channel blockers provides additional benefit."

Cardiovascular • Chronic Kidney Disease • Hypertension

MORE THAN MEETS THE EYE: CHARLES BONNET SYNDROME. (WRMC 2025) - "The patient's only medications were nebivolol and pantoprazole, and she denied use of other substances. Other causes of hallucinations should be excluded, such as neurocognitive disorders, substance use, and medications. However, if this workup is negative, Charles Bonnet Syndrome must be considered as a differential diagnosis."

Age-related Macular Degeneration • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Developmental Disorders • Lewy Body Disease • Macular Degeneration • Mental Retardation • Movement Disorders • Ophthalmology • Parkinson's Disease • Psychiatry • Retinal Disorders • Sleep Disorder • Wet Age-related Macular Degeneration

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial. (PubMed, Cardiovasc Res) - No abstract available

Journal

Posterior Reversible Encephalopathy Syndrome in the Context of McCune-Albright Syndrome: A Case Report. (PubMed, Cureus) - "The patient was treated with systematic administration of anticonvulsants, antihypertensive agents, and nebivolol...MAS covers a spectrum of endocrine dysregulation, resulting in clinical manifestations of high variability. Even in cases of mild hypercortisolemia, it is vital to raise the clinical suspicion of CS, as its reverberations may occur with abrupt onset, like PRES."

Journal • Cardiovascular • CNS Disorders • Cushing’s Disease • Endocrine Disorders • Epilepsy • Genetic Disorders • Hypertension • Ophthalmology • Pulmonary Arterial Hypertension

MOTORS: Nebivolol ANOCA Treatment Randomized Trial (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Spanish Society of Cardiology

New P3 trial • Cardiovascular

Chromatographic Separation and Quantification of Nine Nitrosamine Genotoxic Impurities in a Single Method in Nebivolol Tablet by Using Validated Ultra-Sensitive Liquid Chromatography: Mass Spectrometry Analytical Method. (PubMed, J Chromatogr Sci) - "The LOQ obtained in the range of 9.85-19.62 ppb for nine nitrosamines showed good sensitivity. The results demonstrated that method can be applied to quantify the nitrosamines in nebivolol drug products."

Journal

Combining supervised and unsupervised analyses to quantify behavioral phenotypes and validate therapeutic efficacy in a triple transgenic mouse model of Alzheimer's disease. (PubMed, Biomed Pharmacother) - "Here, we identify age- and genotype-driven differences between 3xTg-AD and non-transgenic control mice using a low-cost, highly customizable behavioral assay that requires little human intervention. Through behavioral phenotyping combining both supervised and unsupervised behavioral classification methods, we are able to validate the preventative effects of the immunosuppressant cyclosporine A in a rodent model of Alzheimer's disease, as well as the partially ameliorating effects of candidate drugs nebivolol and cabozantinib."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders